Research into epigenetic alterations involved in prostate cancer has identified BAZ2A as a potential marker for disease aggression and metastasis. BAZ2A upregulation in prostate cancer is post-transcriptional, resulting from downregulation of microRNA-133a. In PC3 metastatic prostate cancer cells, BAZ2A knockdown impaired proliferation, viability, invasion and migration. BAZ2A and the simiiarly upregulated EZH2 coordinated a metastatic pattern of epigenetic gene silencing. In tissue microarray analyses, BAZ2A expression was an independent predictor of disease recurrence, notably in cases of intermediate-risk disease.